EA202091464A1 - Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита - Google Patents
Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатитаInfo
- Publication number
- EA202091464A1 EA202091464A1 EA202091464A EA202091464A EA202091464A1 EA 202091464 A1 EA202091464 A1 EA 202091464A1 EA 202091464 A EA202091464 A EA 202091464A EA 202091464 A EA202091464 A EA 202091464A EA 202091464 A1 EA202091464 A1 EA 202091464A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- alcoholic
- treatment
- liver disease
- compositions
- fat liver
- Prior art date
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title abstract 2
- 208000019423 liver disease Diseases 0.000 title 1
- 229940120726 Glucagon-like peptide receptor agonist Drugs 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 abstract 1
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Описанное в настоящей заявке является новым способом лечения таких заболеваний, как неалкогольная жировая болезнь печени и неалкогольный стеатогепатит с использованием средства, усиливающего секрецию гормона роста в монотерапии или в комбинации с лекарственным средством, выбранным из антагониста дипептидилпептидазы-4, агониста рецепторов глюкагоноподобного пептида, тиазолидиндиона, антагониста натрий-глюкозного транспортного белка 2-го типа и метформина. Также представлены связанные с ним композиции.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862630361P | 2018-02-14 | 2018-02-14 | |
PCT/US2019/017964 WO2019161025A1 (en) | 2018-02-14 | 2019-02-14 | Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202091464A1 true EA202091464A1 (ru) | 2020-12-07 |
Family
ID=67620042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202091464A EA202091464A1 (ru) | 2018-02-14 | 2019-02-14 | Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита |
Country Status (10)
Country | Link |
---|---|
US (2) | US20210059993A1 (ru) |
EP (1) | EP3781158A4 (ru) |
JP (2) | JP2021513552A (ru) |
KR (2) | KR20200121308A (ru) |
CN (1) | CN111727041A (ru) |
AU (1) | AU2019222736B2 (ru) |
BR (1) | BR112020016613A2 (ru) |
CA (1) | CA3088177A1 (ru) |
EA (1) | EA202091464A1 (ru) |
WO (1) | WO2019161025A1 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113646327A (zh) | 2019-03-29 | 2021-11-12 | 综合医院公司 | 用于治疗肝脏疾病的ghrh或其类似物 |
WO2022059946A1 (ko) * | 2020-09-18 | 2022-03-24 | 서울대학교 산학협력단 | 비알코올성 지방간염 및 간 섬유화의 치료를 위한 약학적 조성물 |
KR20220132312A (ko) | 2021-03-23 | 2022-09-30 | 한국과학기술원 | 간세포의 IFN-γR1 매개 지질생성작용 억제를 통한 비알코올성 지방간 질환의 치료 방법 |
US11969416B1 (en) | 2022-11-03 | 2024-04-30 | Lumos Pharma, Inc. | Compactable oral formulations of ibutamoren |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
WO2005042003A1 (en) * | 2003-10-24 | 2005-05-12 | Merck & Co., Inc. | Enhancement of growth hormone levels with a dipeptidyl peptidase iv inhibitor and a growth hormone secretagogue |
JP2007532495A (ja) * | 2004-04-07 | 2007-11-15 | ガストロテック・ファルマ・アクティーゼルスカブ | グレリン欠乏を治療するための分泌促進薬の使用 |
PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
US20090312302A1 (en) * | 2008-06-17 | 2009-12-17 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders |
WO2019008554A1 (en) * | 2017-07-06 | 2019-01-10 | Conte Anthony | METHOD FOR ORAL TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE |
-
2019
- 2019-02-14 JP JP2020543742A patent/JP2021513552A/ja active Pending
- 2019-02-14 KR KR1020207023368A patent/KR20200121308A/ko active Application Filing
- 2019-02-14 EA EA202091464A patent/EA202091464A1/ru unknown
- 2019-02-14 BR BR112020016613-8A patent/BR112020016613A2/pt unknown
- 2019-02-14 CA CA3088177A patent/CA3088177A1/en active Pending
- 2019-02-14 AU AU2019222736A patent/AU2019222736B2/en active Active
- 2019-02-14 EP EP19755124.5A patent/EP3781158A4/en active Pending
- 2019-02-14 CN CN201980013533.4A patent/CN111727041A/zh active Pending
- 2019-02-14 US US16/961,564 patent/US20210059993A1/en not_active Abandoned
- 2019-02-14 KR KR1020247002905A patent/KR20240015742A/ko active Application Filing
- 2019-02-14 WO PCT/US2019/017964 patent/WO2019161025A1/en unknown
-
2023
- 2023-08-09 US US18/231,977 patent/US20230381158A1/en active Pending
- 2023-12-27 JP JP2023221157A patent/JP2024028337A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019222736A1 (en) | 2020-07-30 |
WO2019161025A1 (en) | 2019-08-22 |
EP3781158A1 (en) | 2021-02-24 |
US20210059993A1 (en) | 2021-03-04 |
KR20240015742A (ko) | 2024-02-05 |
CN111727041A (zh) | 2020-09-29 |
BR112020016613A2 (pt) | 2020-12-22 |
AU2019222736B2 (en) | 2024-08-01 |
JP2024028337A (ja) | 2024-03-04 |
KR20200121308A (ko) | 2020-10-23 |
JP2021513552A (ja) | 2021-05-27 |
CA3088177A1 (en) | 2019-08-22 |
EP3781158A4 (en) | 2022-03-16 |
US20230381158A1 (en) | 2023-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202091464A1 (ru) | Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита | |
EA202091290A1 (ru) | Аналоги инкретина и их применение | |
PE20091193A1 (es) | Proteinas humanas de union a antigenos del gm-csf | |
MX2021012492A (es) | Agonistas de glp-1r y usos de los mismos. | |
MX2018005193A (es) | Proteinas de doble funcion y composicion farmaceutica que comprende las mismas. | |
PH12020551024A1 (en) | Incretin analogs and uses thereof | |
MX2018005194A (es) | Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas. | |
JP2019510739A5 (ru) | ||
MX2020007410A (es) | Formulaciones, composiciones y métodos farmacéuticos de péptido yy. | |
EA202090577A2 (ru) | Соматотропный гормон пролонгированного действия и способы его получения | |
EA200701705A1 (ru) | Антагонисты рецепторы глюкагона, получение и терапевтическое применение | |
MX2021008958A (es) | Proteínas de unión a antígeno del receptor gamma anti-il2. | |
MX2022003251A (es) | Anticuerpo contra gipr y su proteina de fusion con glp-1, y composicion farmaceutica y aplicacion de los mismos. | |
JOP20210326A1 (ar) | أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها | |
MX2021008010A (es) | Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld). | |
MX2020010547A (es) | Anticuerpo agonista del receptor de leptina para usarse en el tratamiento de una disfuncion metabolica o hipoleptinemia. | |
CO2020012621A2 (es) | Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso | |
MX2023008330A (es) | Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos. | |
EA200800181A1 (ru) | Фармацевтическая композиция glp-1 | |
MX2021002655A (es) | Terapia de combinacion para el tratamiento de enfermedad hepatica. | |
MX2021004603A (es) | Dosificacion. | |
MX2023014771A (es) | Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso. | |
BR112022012499A2 (pt) | Peptídeo, composição, métodos para tratar um paciente e para tratar uma doença, e, uso de um peptídeo | |
JP2024508611A (ja) | 方法 | |
WO2016130901A3 (en) | Blockers of the growth hormone receptor in disease prevention and treatment |